10,355 Shares in AstraZeneca PLC $AZNCF Purchased by Vaughan Nelson Investment Management L.P.

Vaughan Nelson Investment Management L.P. bought a new stake in AstraZeneca PLC (OTCMKTS:AZNCF) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 10,355 shares of the company’s stock, valued at approximately $2,042,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Hughes Financial Services LLC acquired a new stake in AstraZeneca during the 4th quarter valued at approximately $34,000. Fairscale Capital LLC acquired a new stake in shares of AstraZeneca in the fourth quarter worth $37,000. Mascoma Wealth Management LLC acquired a new stake in shares of AstraZeneca in the fourth quarter worth $46,000. Aventus Investment Advisors Inc. purchased a new position in shares of AstraZeneca during the first quarter worth $46,000. Finally, Resources Management Corp CT ADV purchased a new position in shares of AstraZeneca during the fourth quarter worth $61,000. Institutional investors and hedge funds own 40.87% of the company’s stock.

AstraZeneca Stock Performance

OTCMKTS AZNCF opened at $187.10 on Tuesday. AstraZeneca PLC has a 1 year low of $122.26 and a 1 year high of $195.00. The company has a fifty day moving average of $187.10 and a 200 day moving average of $186.10.

AstraZeneca Company Profile

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.